The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis
Wirksamkeit und Sicherheit von Immun-Checkpoint-Inhibitoren plus Chemotherapie versus Chemotherapie bei nicht-kleinzelligem Lungenkarzinom: aktualisierte systematische Übersicht und Metaanalyse
PLOS ONE · 06.02.2024 · 19 (2) · e0276318
DOI: 10.1371/journal.pone.0276318 ↗Auf einen Blick
Eine Metaanalyse von 12 Studien bei NSCLC zeigte unter ICI plus Chemotherapie bessere Überlebens- und Ansprechdaten als unter Chemotherapie allein. Die Sicherheit hing vom eingesetzten Checkpoint-Inhibitor ab.
Fragestellung
Sind Immun-Checkpoint-Inhibitoren plus Chemotherapie bei NSCLC wirksamer und sicherer als Chemotherapie allein?
Methode
Systematische Übersicht und Metaanalyse randomisierter kontrollierter Studien; Suche in PubMed, Embase und Cochrane Library bis Februar 2022.
Ergebnisse
12 Studien. Gegenüber Chemotherapie verbesserten ICIs plus Chemotherapie OS (HR 0,79; 95 %-KI 0,74–0,84), PFS (HR 0,62; 95 %-KI 0,59–0,67) und ORR (RR 1,48; 95 %-KI 1,27–1,73).
Einschränkungen
Heterogenität bei PFS und ORR war erhöht.
Schlussfolgerung der Autor:innen
ICIs plus Chemotherapie waren bei NSCLC mit signifikant besserem PFS, ORR und OS verbunden. PD-L1/CTLA-4-Inhibitoren plus Chemotherapie konnten das Risiko schwerer unerwünschter Ereignisse erhöhen, PD-1-Inhibitoren nicht.
Kernaussagen
- OS, PFS und ORR waren unter ICI plus Chemotherapie besser als unter Chemotherapie
- PD-1/PD-L1-Inhibitoren verbesserten die Endpunkte bei weniger leichten TRAEs
- PD-L1/CTLA-4-Inhibitoren erhöhten das Risiko schwerer unerwünschter Ereignisse
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Metaanalyse in der Zeitschrift PLOS ONE, online erschienen am 06.02.2024. Verfasst von Jing Kang und 5 weiteren Autor:innen. Beteiligte Einrichtung: First Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Jilin Province, the Chinese National Natural Science Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Immune-checkpoint inhibitors(ICIs) combined with chemotherapy are emerging as an effective first-line treatment in advanced non-small cell lung cancer (NSCLC); however, reports on the magnitude of effectiveness and safety are conflicting.
Methods
Relevant articles published before February 2022 were searched in PubMed, Embase, and the Cochrane Library. The study included all randomized controlled trials that evaluated ICIs with chemotherapy versus chemotherapy for the treatment of NSCLC. Among the outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and treatment-related adverse events (TRAEs).
Results
Our meta-analysis included a total of 12 studies. Overall analysis indicated that ICIs plus chemotherapy could significantly improve OS (HR = 0.79; 95% CI: 0.74–0.84; I 2 = 44.4%, P = 0.055), PFS (HR = 0.62; 95% CI: 0.59–0.67; I 2 = 75.3%, P = 0.000), and ORR (RR = 1.48; 95% CI: 1.27–1.73; I 2 = 79.0%, P = 0.000) when compared to chemotherapy treatments. Subgroup analysis showed that PD-1/PD-L1 inhibitors combined with chemotherapy significantly improved OS, PFS, and ORR when compared with chemotherapy with decreased grade 1–2 TRAEs. In addition, female patients with nonsquamous histology might receive more OS benefit from ICIs plus chemotherapy when compared to chemotherapy alone. Despite the fact that CTLA-4 inhibitors combined with chemotherapy increased PFS, there were no benefits gained in OS nor ORR. When PD-L1/CTLA-4 inhibitors were added to chemotherapy, the risk of grade 3–5 adverse events increased whereas PD-1 inhibitors did not.
Conclusions
ICIs plus chemotherapy, compared with chemotherapy, were associated with significantly improved PFS, ORR, and OS in NSCLC therapy. However, PD-L1/CTLA-4 inhibitors plus chemotherapy could increase the risk of grade 3–5 adverse events, but not PD-1 inhibitors plus chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- First Hospital of Jilin University, Changchun, China.
- Jilin Medical University, Jilin, China.
- Laboratory of Tumor Targeted Therapy and Translational Medicine, Jilin, China.
ORCID-Profile: Mingxian Li
Förderung
- Natural Science Foundation of Jilin Province
- the Chinese National Natural Science Foundation
Zitieren
APA
Kang, J., Zhang, J., Tian, Z., Xu, Y., Li, J., & Li, M. (2024). The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis. PLOS ONE, 19(2), e0276318. https://doi.org/10.1371/journal.pone.0276318
Vancouver
Kang J, Zhang J, Tian Z, Xu Y, Li J, Li M. The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis. PLOS ONE. 2024;19(2):e0276318. doi:10.1371/journal.pone.0276318
BibTeX
@article{Kang2024,
author = {Kang, Jing and Zhang, Jun and Tian, Zongsheng and Xu, Ye and Li, Jiangbi and Li, Mingxian},
title = {The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {2},
pages = {e0276318},
doi = {10.1371/journal.pone.0276318}
}
EUVIMED